GLP-1 Market
LLY $1410.99 ▼ -0.5% NVO $40.45 ▲ +1.1% PFE $30.67 ▲ +0.5% VKTX $26.83 ▼ -1.6% KLRA $12.15 ▼ -5.5% GPCR $20.47 ▼ -6.4% RHHBY $60.68 ▼ -1.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Frexalimab

Company
Sanofi
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
3 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

3 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 3, 2026

Find a Clinical Trial Near Me

See recruiting studies for Frexalimab and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06500702

    A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

    Not yet reported Sanofi 84 participants Est. completion 2028-02-16 79 sites Stand-alone
    Other conditions: Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
    View official trial listing →
  • Recruiting NCT NCT07325292

    Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

    Not yet reported Sanofi 160 participants Est. completion 2028-11-30 68 sites Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Recruiting NCT NCT07412470

    A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

    Not yet reported, Not yet reported Sanofi 526 participants Est. completion 2033-08-15 73 sites Stand-alone
    Other conditions: Kidney Transplant Rejection
    View official trial listing →
  • Active, not recruiting NCT NCT04879628

    Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

    Not yet reported Sanofi 129 participants Est. completion 2027-08-23 37 sites
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Active, not recruiting NCT NCT05039840

    Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

    Not yet reported Sanofi 109 participants Est. completion 2026-11-24 73 sites Stand-alone
    Other conditions: Systemic Lupus Erythematosus
    View official trial listing →
  • Active, not recruiting NCT NCT06111586

    Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)

    Not yet reported Sanofi 197 participants Est. completion 2030-10-29 79 sites Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Active, not recruiting NCT NCT06141473

    Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

    Not yet reported Sanofi 1655 participants Est. completion 2027-05-06 382 sites Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Active, not recruiting NCT NCT06141486

    Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

    Not yet reported Sanofi 943 participants Est. completion 2028-03-24 311 sites Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.